Department of Medicine; University of Wisconsin; Madison, WI USA.
Oncoimmunology. 2012 Dec 1;1(9):1546-1556. doi: 10.4161/onci.22564.
Vaccines encoding xenoantigens, "non-self" proteins that are highly homologous to their autologous counterparts, have been investigated as a means to increase immunogenicity and overcome tolerance to "self" antigens. We have previously shown that DNA vaccines encoding native prostatic acid phosphatase (PAP) were able to elicit PAP-specific T cells in both rats and humans, but required multiple immunization courses. In this study, we investigated in a preclinical model whether immunizations with a DNA vaccine encoding a xenoantigen could elicit a cross-reactive immune response to the native protein, potentially requiring fewer immunizations. Lewis rats were immunized with a DNA vaccine encoding human PAP and splenocytes from immunized rats were screened with a human peptide library containing overlapping, 15-mer PAP-derived peptides using T-cell proliferation and interferon γ (IFNγ) release as measures of the immune response. One dominant PAP-specific, RT1.A(l)-restricted, epitope was identified. Direct immunization with the immunodominant peptide (HP(201-215)) containing this epitope demonstrated that it included a naturally presented MHC Class I epitope recognized by CD8(+) T cells in Lewis rats. However, no cross-reactive immune response was elicited to the corresponding rat peptide despite a difference of only three amino acids. Immunization with DNA vaccines encoding rat PAP (rPAP) in which this foreign dominant epitope was included as well as with DNA vaccines coding for a variant of the xenoantigen from which this epitope was deleted, did not elicit responses to the native antigen. Overall, these results indicate that the immunization with a xenoantigen-coding DNA vaccine can lead to an immune response which potentially favors foreign epitopes and hence limits any cross-reactive response to the native antigen.
疫苗编码异种抗原,即与自身蛋白高度同源的“非自身”蛋白,已被研究用于提高免疫原性并克服对“自身”抗原的耐受。我们之前已经表明,编码天然前列腺酸性磷酸酶(PAP)的 DNA 疫苗能够在大鼠和人类中引发 PAP 特异性 T 细胞,但需要多次免疫接种。在这项研究中,我们在临床前模型中研究了用编码异种抗原的 DNA 疫苗免疫是否能引发对天然蛋白的交叉反应性免疫应答,从而可能需要较少的免疫接种次数。Lewis 大鼠用编码人 PAP 的 DNA 疫苗免疫,用含有重叠 15 肽的人肽文库筛选免疫大鼠的脾细胞,以 T 细胞增殖和干扰素γ(IFNγ)释放作为免疫应答的衡量标准。鉴定出一个主要的 PAP 特异性、RT1.A(l)-限制性表位。用包含该表位的免疫显性肽(HP(201-215))直接免疫,表明它包含一个由 Lewis 大鼠 CD8+T 细胞识别的天然呈递 MHC Ⅰ类表位。然而,尽管只有三个氨基酸的差异,针对相应的大鼠肽却没有引发交叉反应性免疫应答。用包含该外来显性表位的编码大鼠 PAP(rPAP)的 DNA 疫苗以及用删除该表位的编码该异种抗原的变体的 DNA 疫苗免疫,均不能引发对天然抗原的反应。总的来说,这些结果表明,用编码异种抗原的 DNA 疫苗免疫可以引发一种免疫应答,这种应答可能有利于外来表位,从而限制对天然抗原的任何交叉反应性应答。